Core Viewpoint - Madrigal Pharmaceuticals has entered an exclusive global license agreement with Suzhou Ribo Life Science for six preclinical small interfering RNA (siRNA) programs aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) [1][6] Company Overview - Madrigal Pharmaceuticals is focused on developing novel therapeutics for MASH, a liver disease with significant unmet medical needs [14] - The company’s lead product, Rezdiffra (resmetirom), is the first medication approved for MASH with moderate to advanced fibrosis [14] - Madrigal's pipeline now includes over 10 programs targeting various drivers of MASH, with Rezdiffra serving as the foundational therapy [2][3] Research and Development Strategy - The R&D strategy emphasizes innovative compounds targeting validated mechanisms of disease to improve patient outcomes [2] - siRNAs are highlighted for their precision in gene silencing, potentially complementing the effects of Rezdiffra [3][5] - The company plans to initiate IND-enabling activities for initial siRNA candidates in 2026 [5] Financial Aspects - Ribo will receive an upfront payment of $60 million, with potential cumulative payments reaching $4.4 billion based on milestone achievements, in addition to royalties on net sales [6] Market Context - MASH is a leading cause of liver transplantation, particularly among women, and is rapidly growing in prevalence [7][9] - Patients with moderate to advanced liver fibrosis face significantly higher risks of liver-related mortality, underscoring the urgency for effective treatments [8] Product Information - Rezdiffra is prescribed alongside diet and exercise for adults with MASH and is currently undergoing studies to confirm its clinical benefits [10]

Core Viewpoint - BioArctic AB will release its fourth quarter report for October - December 2025 on February 18, 2026, at 08:00 a.m. CET, followed by a presentation for investors, analysts, and media at 09:30 a.m. CET [1][2]. Company Information - BioArctic AB is a Swedish biopharma company focused on innovative treatments for neurodegenerative diseases, including Alzheimer's disease [2]. - The company developed Leqembi® (lecanemab), the first drug proven to slow the progression of early Alzheimer's disease and reduce cognitive impairment [2]. - BioArctic has a diverse research portfolio, including antibodies targeting Parkinson's disease and ALS, as well as additional Alzheimer's projects [2]. - The company utilizes its proprietary BrainTransporter™ technology to enhance treatment efficacy by transporting antibodies across the blood-brain barrier [2]. Event Details - The presentation on the fourth quarter report will include comments from CEO Gunilla Osswald and CFO Anders Martin-Löf, followed by a Q&A session [1]. - Participants can join via webcast or teleconference, with options to submit questions during the event [1][2].

Core Insights - Ascendis Pharma A/S is focused on developing treatments for unmet medical needs, with notable products including SKYTROFA for growth hormone deficiency and other treatments in its pipeline [1] Group 1: Stock Performance and Analyst Sentiment - The consensus price target for Ascendis Pharma's stock has increased from $270.50 a year ago to $307.33 in the last month, indicating growing optimism among analysts [2] - Bank of America Securities analyst Tazeen Ahmad has set a conservative price target of $161, reflecting some caution in the market [2] Group 2: Financial Performance - Ascendis Pharma reported Q3 revenues of €213.6 million, nearly four times higher than the previous year, driven by Yorvipath and SKYTROFA [3][5] - The company achieved operating profitability for the quarter, indicating strong financial performance [3] Group 3: Upcoming Events and Growth Prospects - The FDA PDUFA date for TransCon CNP on February 28th is critical, as approval could open a multi-billion-euro market for the company [4][5] - Ascendis Pharma has a solid cash position of €539 million, which supports continued investment in its pipeline and reduces near-term dilution risk [4]

Core Viewpoint - A class action has been filed against Inovio Pharmaceuticals, Inc. for allegedly misleading investors regarding the approval process for its CELLECTRA device and the INO-3107 Biologics License Application (BLA) [1] Group 1: Allegations and Issues - The complaint alleges that Inovio failed to disclose deficiencies in the manufacturing of its CELLECTRA device [1] - It is claimed that Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024 due to these manufacturing issues [1] - The company reportedly lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review [1] Group 2: Impact on Stock Price - Following a press release on August 8, 2024, revealing a delay in the INO-3107 BLA submission to mid-2025, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 per share on August 9, 2024 [1] - On December 29, 2025, after announcing that the FDA accepted the INO-3107 BLA on a standard review timeline, Inovio's stock price dropped by $0.56 per share, or 24.45%, closing at $1.73 per share [1] Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Inovio, with a deadline to submit papers to the court by April 7, 2026 [1] - The lead plaintiff will represent other class members in directing the litigation, but participation is not required for recovery [1]

Core Insights - Gilead Sciences reported a strong performance in its HIV segment, with full-year sales reaching $20.8 billion, a 6% increase year-over-year, and fourth-quarter sales hitting a record $5.8 billion, also up 6% [1][6]. Financial Performance - Total product sales for the fourth quarter were $7.9 billion, a 5% increase year-over-year, while excluding Veklury, sales were $7.7 billion, up 7% [2]. - For the full year 2025, Gilead's total product sales were $28.9 billion, up 1% from 2024, exceeding guidance [3]. - The base business sales, excluding Veklury, were $28.0 billion, up 4% year-over-year, and would have been 8% without the impact of the Medicare Part D redesign [2][6]. HIV Business Highlights - The HIV business faced a $900 million headwind from the Part D redesign in 2025, but management indicated that excluding this impact, HIV sales grew by 10% [1]. - Biktarvy, a key treatment, generated fourth-quarter sales of $4.0 billion, up 5% year-over-year, and full-year sales of $14.3 billion, up 7% [7]. - The injectable HIV prevention product Sunlenca generated $150 million in 2025, with management forecasting about $800 million in revenue for 2026 [8][9]. Liver and Oncology Performance - Gilead's liver disease business grew 6% in 2025 to $3.2 billion, with fourth-quarter sales of $844 million, up 17% year-over-year, driven by the adoption of Livdelzi [12]. - In oncology, Trodelvy sales rose 6% in 2025 to $1.4 billion, with fourth-quarter sales of $384 million, up 8% year-over-year [13]. Future Guidance and Pipeline - For 2026, Gilead expects total product sales of $29.6 billion to $30.0 billion, with base business sales projected to grow 4% to 5% [21]. - The company plans multiple potential launches in 2026, including Trodelvy for first-line TNBC and a combination therapy for HIV [5][18]. - Management anticipates a product gross margin of about 87% and non-GAAP diluted EPS of $8.45 to $8.85 for 2026 [22]. Capital Return Strategy - Gilead returned $5.9 billion to shareholders in 2025, including $1.9 billion in share repurchases, and aims to return at least 50% of free cash flow to shareholders [24].

Financial Data and Key Metrics Changes - For Q4 2025, total revenues were approximately $599 million, with cabozantinib franchise net product revenues of $546.6 million, and CABOMETYX net product revenues at $544.7 million [15][18] - Gross-to-net for the cabozantinib franchise in Q4 2025 was 28.5%, lower than the previous quarter, primarily due to lower PHS and 340B volume [15][16] - GAAP net income for Q4 2025 was approximately $244.5 million, or $0.92 per share basic, and $0.88 per share diluted [17] - Non-GAAP net income was approximately $259.5 million, or $0.97 per share basic, and $0.94 per share diluted [18] - Cash and marketable securities at year-end 2025 were approximately $1.66 billion, with $954 million spent on share repurchases during the fiscal year [18][19] Business Line Data and Key Metrics Changes - The cabozantinib business maintained strong performance, with U.S. CABO franchise net product revenues growing 17% to approximately $2.12 billion for the full year 2025 [10] - CABOMETYX continued to be the leading TKI for renal cell carcinoma (RCC) and the market leader for neuroendocrine tumors in the oral second-line-plus segment [20] - CABOMETYX TRX volume grew 15% in Q4 2025 compared to Q4 2024, outpacing the market basket growth rate of 7% [21] Market Data and Key Metrics Changes - CABOMETYX's market share in the oral TKI market increased from 43% to 46% from Q4 2024 to Q4 2025 [20] - CABOMETYX revenue in neuroendocrine tumors exceeded $100 million in 2025, indicating strong market demand [23] Company Strategy and Development Direction - The company aims to build a multi-franchise business in solid tumor oncology, focusing on cabozantinib and zanzalintinib, with a strategy that encompasses products, tumor indications, and modalities [8][9] - The company is preparing for the potential launch of zanzalintinib in colorectal cancer (CRC) and has expedited the build-out of its GI sales team to support this initiative [11][23] - Business development activities are focused on late-stage assets in GU and GI spaces, with an emphasis on pay-for-success transactions [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2026 being a transformational year, with expectations for continued growth in cabozantinib and the potential launch of zanzalintinib [35] - The company is actively engaging with regulators regarding the NDA for zanzalintinib, with a PDUFA target action date set for December 3, 2026 [26][28] Other Important Information - The company reported a sequential increase in operating expenses due to higher manufacturing costs, NDA filing fees, and personnel expenses [16][17] - The company has approximately $590 million remaining under its stock repurchase plan authorized in October 2025 [19] Q&A Session Summary Question: Duration of small manufacturer discount for Zanza and share repurchase cadence - Management indicated that the small manufacturer exemptions are tied to having a single product as the majority revenue source, which is expected to remain for the foreseeable future [39] - Share repurchases will continue as long as the company feels undervalued, with a commitment to complete the remaining authorization this year [40] Question: 340B purchasing behavior and Part D redesign impact - Management noted variability in 340B purchasing behavior and expects this to continue, which could impact gross-to-net [42] - The company plans to optimize its channel for Zanza based on experiences from cabozantinib [44] Question: STELLAR-316 population size and timeline - The estimated population for STELLAR-316 is around 20,000-25,000 patients who are MRD positive after definitive therapy [47] Question: Revenue potential for NET and market dynamics - Management expressed confidence in the growth potential for neuroendocrine tumors, emphasizing the importance of community outreach and the expansion of the GI sales team [51] Question: Non-clear cell RCC market size and outcomes - Non-clear cell RCC represents approximately 20% of RCC, and the company is optimistic about the potential benefits of its pivotal study in this underserved population [82]

Core Insights - The biopharmaceutical company is planning to introduce two cancer therapies and an additional HIV treatment option within this year [1] Company Developments - The company is focusing on expanding its product offerings in the oncology and HIV treatment sectors [1]

Core Insights - DBV Technologies will present additional data from the VITESSE Phase 3 study of the VIASKIN® Peanut Patch for children aged 4-7 at the AAAAI 2026 Annual Meeting in Philadelphia from February 27 to March 2, 2026 [1] - The company will host a product theater featuring allergists discussing the potential of epicutaneous immunotherapy (EPIT) in food allergy treatment and the impact of early intervention [2] Company Overview - DBV Technologies is a late-stage biopharmaceutical company focused on developing treatments for food allergies and other immunologic conditions with significant unmet medical needs [4] - The company is investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which can cause severe reactions including anaphylaxis [4] - The VIASKIN® patch aims to introduce microgram amounts of biologically active compounds to the immune system through intact skin, representing a non-invasive treatment approach [4] Event Details - The oral abstract presentation titled "VITESSE Phase 3 Study: Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children 4 Through 7 Years of Age" will take place on February 28, 2026 [3][6] - The product theater session titled "Epicutaneous Immunotherapy (EPIT): Shaping the Future of Pediatric Food Allergy Treatment" will also occur on February 28, 2026 [3][6] - DBV will exhibit at booth 1527 at the AAAAI exhibit hall to provide more information about epicutaneous immunotherapy and the VIASKIN® Peanut Patch [3]

Core Viewpoint - Avadel Pharmaceuticals plc has received approval from the Irish High Court for a scheme of arrangement that will allow Alkermes plc to acquire all issued shares of Avadel, marking a significant step in the Proposed Transaction [1][2]. Company Overview - Avadel Pharmaceuticals plc is a biopharmaceutical company focused on innovative medication solutions, with its commercial product LUMRYZ™ being the first and only once-at-bedtime oxybate approved for treating narcolepsy in patients aged 7 and older [5]. Proposed Transaction Details - The Proposed Transaction involves Alkermes acquiring the entire issued and to be issued ordinary share capital of Avadel [1]. - The completion of the Proposed Transaction is contingent upon the delivery of a copy of the Court Order sanctioning the Scheme to the Registrar of Companies [2]. - The Court Order is expected to be processed by February 11, 2026, with the Scheme taking effect on February 12, 2026, leading to the last trading day of Avadel Shares on Nasdaq being February 11, 2026 [3].

BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, Series C non-voting convertible preferred stock. All of the securities are being offered by Galecto. In addition, Galecto intends to ...